Andrea Kahn, MD | |
110 S North St, Seaford, DE 19973-3508 | |
(302) 629-0656 | |
(302) 629-3076 |
Full Name | Andrea Kahn |
---|---|
Gender | Female |
Speciality | Ophthalmology |
Location | 110 S North St, Seaford, Delaware |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285716043 | NPI | - | NPPES |
180002813 | Other | DE | RAILROAD MEDICARE |
1285716043 | Medicaid | DE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | C1-0002547 (Delaware) | Primary |
Mailing Address | Practice Location Address |
---|---|
Andrea Kahn, MD 110 S North St, Seaford, DE 19973-3508 Ph: (302) 629-0656 | Andrea Kahn, MD 110 S North St, Seaford, DE 19973-3508 Ph: (302) 629-0656 |
News Archive
A gene crucial for embryonic development can quickly become a potent cancer promoter in adult mice after a genetic misalignment, according to researchers from Fox Chase Cancer Center, causing white blood cells to become cancerous spontaneously.
Six years ago, he was paralyzed in a diving accident. Today, he participates in clinical sessions during which he can grasp and swipe a credit card or play a guitar video game with his own fingers and hand. These complex functional movements are driven by his own thoughts and a prototype medical system that are detailed in a study published online today in the journal Nature.
The Partnership to Fight Chronic Disease (PFCD) today released an updated comparison of chronic care provisions contained within health reform legislation to reflect the amended Senate Finance Committee proposal. The amended "Chairman's Mark" includes numerous provisions to prevent and manage chronic disease, the top cost driver in health care, as do the two other major pieces of health reform legislation under consideration in Congress.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.
› Verified 6 days ago
Phillip Demott, OD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 8500 Herring Run Rd, Seaford, DE 19973 Phone: 302-629-6691 Fax: 302-629-7963 | |
Dr. Michael James Munro, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1303 Bridgeville Hwy, Seaford, DE 19973 Phone: 302-629-6816 Fax: 302-990-4333 |